LiquidGx™

LIQUID BIOPSY FOR NON-INVASIVE CANCER TESTING

An alternative for when tissue-based biopsy is not available

Designed for precision treatment and drug resistance monitoring

- Quantitatively detects cancer-driving variants and drug resistant markers early with a superior limit-of-detection
- Actionable results help guide therapeutic decisions related to targeted cancer therapy
- Requires two 10ml tubes of blood that can easily be worked into patient workflow
- Detects single nucleotide variants (SNVs), gene fusions, insertion and deletions (Indels), copy number variations (CNVs), and microsatellite instability (MSI) status
- Input includes both ctDNA and ctRNA allowing for optimal fusion detection

qPCR

ALK	BRAF	EGFR	KRAS

- Single gene analytes via qPCR
- Can be run together or individually
- Limit-of-detection 0.01%
- Rapid turnaround time of <3 business days
- EGFR T790M and C797S variant detection for drug resistance monitoring included

NGS

AKT1	ALK	BRAF	EGFR	ERBB2	HRAS
KIT	KRAS	MAP2K1	MET	NRAS	PDGFRA
PIK3CA	PTEN	RET	ROS1	TP53	

- Next Generation Sequencing test, coverage of >170 variants in 17 genes frequently mutated in cancer
- Includes MSI for selection of anti-PD1 therapy
- Limit-of-detection 0.1% (SNV, Indel, fusion), 2% (MSI), 2.5 total gene copies (CNV)
- Turnaround time of 3-5 business days
- Ability to detect novel fusions



Relevant Solid Tumor Therapies

Afatinib (Gilotrif®)
Alectinib (Alecensa®)
Bevacizumab (Avastin®)
Brigatinib (Alunbrig®)
Cabozantinib (Cometriq®)
Ceritinib (Zykadia®)
Cetuximab (Erbitux®)
Crizotinib (Xalkori®)
Dabrafenib (Tafinlar®)
Erlotinib (Tarceva®)
Everolimus (Afinitor®)
Gefitinib (Iressa®)
Imatinib (Gleevec®)
Nilotinib (Tasigna®)
Nivolumab (Opdivo®)
Osimertinib (Tagrisso®)
Panitumumab (Vectibix®)
Pembrolizumab (Keytruda®)
Sorafenib (Nexavar®)
Sunitinib (Sutent®)
Temsirolimus (Torisel®)
Trametinib (Mekinist®)
Trastuzumab (Herceptin®)
Vandetanib (Caprelsa®)
Vemurafenib (Zelboraf®)

admera health

admerahealth.com
T: 908-222-0533 | 844-4admera

LiquidGx™



Clear, color-coded recommendations:

- FDA-approved drugs for that indication
- FDA-approved drugs for other indications that may be beneficial
- Drugs that will likely not show any benefit due to the presence of resistance markers
- Easy to read with relevant clinical trial information based on geography (up to 5 trials listed per variant found)

MSI can predict a predisposition to mutations as a result from impaired DNA mismatch repair (MMR) and effective anti-PD-1 therapy

MSI status is determined by detecting the length of mononucleotide repeats at five genomic sites (BAT-25, BAT-26, NR-21, NR-24, and NR-27)



A shift in repeat length (formation of a second peak) observed in the **cell-free DNA (cfDNA)** compared to **genomic DNA (gDNA)** at 3 or more sites indicates MSI-High



T-Cell cannot recognize tumor cell as foreign



With anti-PD1 therapy, T-Cell can now recognize tumor cell as foreign



Quantifiably detects variants, including drug resistant markers

Ideal for longitudinal monitoring

admera health

admerahealth.com
T: 908-222-0533 | 844-4admera